A pharmaceutical composition in solid form containing particulate cilostazol or a salt thereof, a cellulose, a diluent, and a lubricant. The pharmaceutical composition features an in vivo plasma profile for cilostazol of C24h/Cmax > 0.25. Also disclosed is a method of preparing the above-described pharmaceutical composition.